Overview
US biopharmaceutical firm's 2025 net loss slightly beat analyst expectations
Outlook
Aardvark expects to provide further guidance on ARD-101 and ARD-201 programs in Q2 2026
Company's cash position supports projected operations into Q2 2027
Result Drivers
R&D SPENDING - Higher research and development expenses driven by increased external costs for ARD-101 and personnel-related expenses
G&A EXPENSES - General and administrative expenses rose due to higher personnel, legal, and professional services costs
Company press release: ID:nGNX6slMSw
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
Slight Beat*
-$57.59 mln
-$58.16 mln (12 Analysts)
FY Income from Operations
-$62.7 mln
FY Operating Expenses
$62.7 mln
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Aardvark Therapeutics Inc is $21.00, about 416% above its March 20 closing price of $4.07
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
